Loading…
Pyxis Oncology, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -78.6% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $1.15 | $1.56 | $1.80 | $1.34 | $10.97 | |
| P/S | — | 5.2x | 6.0x | — | — | — |
| P/B | 0.8x | 1.4x | 0.8x | 0.8x | 0.3x | 1.4x |
| EPS | -$1.28 | -$1.32 | -$1.85 | -$3.65 | -$8.95 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ACIUAC Immune SA | $2.73 | — | 6.3x | — | -78.53% | $271.44M |
| ACBAurora Cannabis Inc | $4.22 | — | 0.7x | — | -9.40% | $267.17M |
| TRDAEntrada Therapeutics, Inc. | $7.00 | — | 0.9x | — | -54.09% | $272.56M |
| ANIKAnika Therapeutics, Inc. | $20.38 |
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Company description provided by Yahoo Finance.
| Profit margin | — | -574.55% | -478.95% | — | — | — |
| ROE | -64.04% | -149.08% | -64.04% | -58.70% | -75.06% | -29.07% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 2.0x |
| — |
| -2.19% |
| $272.68M |
| LYELLyell Immunopharma, Inc. | $11.15 | — | 1.1x | — | -93.28% | $273.23M |
| OSUROrasure Technologies Inc | $3.99 | — | 0.9x | — | -14.07% | $275.18M |